Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Free Cash Flow of -$18.8 million for Q1 2026, down 22.95% year-over-year from -$24.3 million in Q1 2025, and down 10.65% quarter-over-quarter from -$17.0 million in Q4 2025.
Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Free Cash Flow data on file, last reported at -$18.8 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$18.8 million, down 22.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.9 million (down 945.09% YoY), and the FY2025 annual result was -$60.4 million, down 2319.03% from the prior year.
- Free Cash Flow slipped to -$18.8 million in Q1 2026 per FULC's latest filing, from -$17.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $58.9 million in Q2 2024 and troughed at -$28.7 million in Q2 2022.
- A 5-year average of -$15.9 million and a median of -$19.2 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 379.56% in 2024, then slumped 123.46% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$17.9 million in 2022, then dropped by 29.99% to -$23.2 million in 2023, then grew by 27.44% to -$16.9 million in 2024, then dropped by 0.56% to -$17.0 million in 2025, then retreated by 10.65% to -$18.8 million in 2026.
- Business Quant data shows FULC's Free Cash Flow at -$18.8 million in Q1 2026, -$17.0 million in Q4 2025, and -$14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -18.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.76 Mn |
| Mar 31, 2026 | -18.76 Mn |
| Dec 31, 2025 | -16.95 Mn |
| Dec 31, 2025 | -16.95 Mn |
| Sep 30, 2025 | -14.35 Mn |
| Sep 30, 2025 | -14.35 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Dec 31, 2024 | -16.86 Mn |
| Dec 31, 2024 | -16.86 Mn |
| Sep 30, 2024 | -19.23 Mn |
| Sep 30, 2024 | -19.23 Mn |
| Jun 30, 2024 | 58.91 Mn |
| Jun 30, 2024 | 58.91 Mn |
| Mar 31, 2024 | -25.31 Mn |
| Mar 31, 2024 | -25.31 Mn |
| Dec 31, 2023 | -23.24 Mn |
| Dec 31, 2023 | -23.24 Mn |